Gastrointestinal Safety Assessment of GLP-1 Receptor Agonists in the US: A Real-World Adverse Events Analysis from the FAERS Database
Gastrointestinale Sicherheitsbewertung von GLP-1-Rezeptoragonisten in den USA: Analyse von Spontanmeldungen aus der FAERS-Datenbank
Diagnostics · 16.12.2024 · 14 (24) · 2829
DOI: 10.3390/diagnostics14242829 ↗Auf einen Blick
In der FAERS-Datenbank wurden unter GLP-1-Rezeptoragonisten gastrointestinale UAW und Folgen analysiert. Semaglutid und Exenatid zeigten dabei auffällige Signale für bestimmte gastrointestinale Ereignisse.
Fragestellung
Welche gastrointestinalen UAW und unerwünschten Folgen sind in der FAERS-Datenbank mit GLP-1-Rezeptoragonisten assoziiert?
Methode
Retrospektive Pharmakovigilanzstudie mit Daten aus der US-FAERS-Datenbank (2007–2023); Auswertung mit deskriptiver Analyse, ROR, PRR, Bayesian confidence propagation neural network und multivariater logistischer Regression.
Ergebnisse
187.757 UAW mit GLP-1-Rezeptoragonisten, davon 16.568 gastrointestinale UAW in den USA. Semaglutid war mit Übelkeit, Erbrechen und verzögerter Magenentleerung assoziiert; Exenatid mit Pankreatitis und Tod.
Schlussfolgerung der Autor:innen
Die FAERS-Analyse zeigt, dass GLP-1-Rezeptoragonisten, besonders Semaglutid und Exenatid, mit spezifischen gastrointestinalen UAW assoziiert sind. Die Autor:innen betonen die Bedeutung der Überwachung und Sicherheit.
Kernaussagen
- 16.568 gastrointestinale UAW wurden in den USA gemeldet
- Semaglutid: Signale für Übelkeit, Erbrechen und verzögerte Magenentleerung
- Exenatid: Assoziation mit Pankreatitis und Tod
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 16.12.2024. Verfasst von Samuel Prince Osei und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, North Dakota State University, Fargo, ND 58108, USA. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly used to treat obesity and diabetes but are linked to a variety of gastrointestinal (GI) adverse events (AEs). Real-world data on GLP-1 RA-related GI AEs and outcomes are limited. This study assessed GI AEs and adverse outcomes using the US FDA Adverse Event Reporting System (FAERS).
Methods
This retrospective pharmacovigilance study used the US FDA FAERS database (2007–2023). We searched GLP-1 RA medications, AEs, and adverse outcomes. Demographic, treatment indication, and AE data were collected. Descriptive analysis involved frequencies and percentages, while reporting odds ratio (ROR), proportional reporting ratio, Bayesian confidence propagation neural network, and multivariate logistic regression were used to analyze GLP-1 RA-related GI AEs and outcomes.
Results
From 2007 to 2023, a total of 187,757 AEs were reported with GLP-1 RAs, and 16,568 were GLP-1 RA-associated GI AEs in the US. Semaglutide was linked to higher odds of nausea (IC025: 0.151, βCoeff: 0.314), vomiting (IC025: 0.334, βCoeff: 0.495), and delayed gastric emptying (IC025: 0.342, βCoeff: 0.453). Exenatide was associated with pancreatitis (IC025: 0.601, βCoeff: 0.851) and death (ROR: 4.50, IC025: 1.101). Overall, semaglutide had a broader range of notable adverse effects; by comparison, dulaglutide and liraglutide use was associated with fewer significant GI AEs.
Conclusions
Analysis of the FAERS data reveals that GLP-1 RAs, particularly semaglutide and exenatide, are significantly associated with specific GI AEs, such as nausea, vomiting, delayed gastric emptying, and pancreatitis. Clinicians should be aware of these potential risks to ensure optimal monitoring and patient safety. This study demonstrated the utility of pharmacovigilance data in identifying safety signals, which can inform future pharmacoepidemiological investigations to confirm causal relationships. Clinicians should be aware of these potential risks to ensure optimal monitoring and patient safety.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Public Health, North Dakota State University, Fargo, ND 58108, USA.
- Faculty of Health Sciences, Simon Fraser University, Burnaby, BC V5A 1S6, Canada.
- Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z1, Canada.
- Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL 32224, USA.
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.
ORCID-Profile: Edwin Akomaning, Wafa A Aldhaleei, Akshaya Srikanth Bhagavathula
Zitieren
APA
Osei, S. P., Akomaning, E., Florut, T. F., Sodhi, M., Lacy, B. E., Aldhaleei, W. A., & Bhagavathula, A. S. (2024). Gastrointestinal Safety Assessment of GLP-1 Receptor Agonists in the US: A Real-World Adverse Events Analysis from the FAERS Database. Diagnostics, 14(24), 2829. https://doi.org/10.3390/diagnostics14242829
Vancouver
Osei SP, Akomaning E, Florut TF, Sodhi M, Lacy BE, Aldhaleei WA, et al. Gastrointestinal Safety Assessment of GLP-1 Receptor Agonists in the US: A Real-World Adverse Events Analysis from the FAERS Database. Diagnostics. 2024;14(24):2829. doi:10.3390/diagnostics14242829
BibTeX
@article{Osei2024,
author = {Osei, Samuel Prince and Akomaning, Edwin and Florut, Teodora Francesca and Sodhi, Mohit and Lacy, Brian E and Aldhaleei, Wafa A and Bhagavathula, Akshaya Srikanth},
title = {Gastrointestinal Safety Assessment of GLP-1 Receptor Agonists in the US: A Real-World Adverse Events Analysis from the FAERS Database},
journal = {Diagnostics},
year = {2024},
volume = {14},
number = {24},
pages = {2829},
doi = {10.3390/diagnostics14242829}
}
EUVIMED